GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
2

20/20 Biolabs, Inc. Common Stock AIDX · USD

US listing · 🇺🇸 United States

Compare

0.20

+1.88%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About 20/20 Biolabs, Inc. Common Stock

From its filings with the US Securities and Exchange Commission

SEC filings

20/20 Biolabs, Inc. Common Stock is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AIDX. The SEC classifies its business as testing laboratories. In the fiscal year to 31 December 2025, it reported revenue of $2.0m and a net loss of $3.7m. At that date it held total assets of $4.1m and shareholders' equity of −$19,225.

Read the filing on SEC.gov ↗

Company facts

Listed since
19 Feb 2026
Employees
4
Head office
9430 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Incorporated in
DE
Classification
Services-Testing Laboratories
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • 20/20 Biolabs' OneTest for Cancer detects multiple cancers early through AI-powered blood tests.
  • CLIAx provides CLIA laboratory services for overseas diagnostics start-ups in Gaithersburg.
  • OneTest for Longevity measures inflammatory biomarkers for chronic disease prevention.

Weaknesses

  • 20/20 Biolabs has only 4 employees, limiting operational capacity.
  • The company's 2026 listing date may delay market entry and revenue generation.
  • Gaithersburg headquarters restricts access to global talent pools.

Opportunities

  • Expanding CLIAx services to support more overseas diagnostics start-ups globally.
  • Growing demand for AI-driven blood tests in the Health Care sector.
  • Potential partnerships with US healthcare providers for OneTest for Cancer.

Threats

  • Competition from established diagnostics companies in the US market.
  • Regulatory challenges in the Health Care sector for new blood tests.
  • Economic downturns affecting healthcare spending in the US.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.